LivaNova (LIVN) Stock Analysis & Winston Score

LivaNova is a medical device company that makes two main types of products: machines that help the heart work properly during surgery, and small implanted devices that treat epilepsy and depression. Its cardiopulmonary products are used by hospitals during open-heart surgeries, while its neuromodulation devices — particularly the vagus nerve stimulator — are implanted in patients whose seizures or depression don't respond well to medication. The company sells to hospitals, surgeons, and specialty clinics around the world. LivaNova earns money by selling its hardware devices and the disposable components used during heart surgeries, which creates a recurring revenue stream. The company operates globally, with a strong presence in Europe and North America, and generates roughly $1.2 billion in annual revenue. Its vagus nerve stimulator has a long track record and regulatory approvals that are difficult for competitors to replicate quickly, but the company faces risk from slower-than-expected adoption of its newer depression treatment indication, which is central to its long-term growth story.